Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00980538 · ClinicalTrials.gov registry record · Phase 3
TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants
A Phase 3 study of HIV Infections and HIV-1, sponsored by Janssen Sciences Ireland UC.
- Active
- Registry status
- Phase 3
- Development phase
- 180
- Enrollment target
- 20
- Study locations
NCT00980538 is a Phase 3 study of HIV Infections and HIV-1 that is active but no longer recruiting, run by Janssen Sciences Ireland UC. The registered enrollment target is 180 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (60% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT00980538, a Phase 3 study of HIV Infections and HIV-1, is active but no longer recruiting, sponsored by Janssen Sciences Ireland UC.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 180 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to provide etravirine (ETR) through this trial until participants can be switched to locally available ETR-based treatment regimens (that is, commercially available and reimbursed, or accessible through another source \[example, access program or government program\]), or local standard of care, as appropriate.
Conditions Studied
Interventions
- DRUG Etravirine
Study Locations (20)
Other
- - Buenos Aires
- - Ciudad Autonoma de Buenos Aire
- - Belo Horizonte
- - Ribeirão Preto
- - Rio de Janeiro
- - Lyon
- - Paris
- - Panama City
- - Rio Piedras
- - Bucharest
- - Bloemfontein
- - Boksburg
- - Cape Town
- - Dundee
- - Durban
California
- - Los Angeles
District of Columbia
- - Washington D.C.
New York
- - New York
Pennsylvania
- - Philadelphia
Quebec
- - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2009-12-09 |
| Est. Completion | 2026-04-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00980538
The ClinicalTrials.gov registry entry for NCT00980538 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (60% lower). The listed sponsor is Janssen Sciences Ireland UC, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Etravirine is the first listed.
NCT00980538 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, California, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT00980538 about?
NCT00980538 is a clinical study titled "TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants". The purpose of this study is to provide etravirine (ETR) through this trial until participants can be switched to locally available ETR-based treatment regimens (that is, commercially available and reimbursed, or accessible through another source \[example, access program or government program\]), o...
What is the current status of trial NCT00980538?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 180 participants. The study started on 2009-12-09. Estimated completion is 2026-04-16.
What conditions does trial NCT00980538 study?
This clinical trial studies the following conditions: HIV Infections, HIV-1.
What interventions are being tested in trial NCT00980538?
The interventions under investigation include: Etravirine (DRUG).
Who is sponsoring clinical trial NCT00980538?
This trial is sponsored by Janssen Sciences Ireland UC, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00980538 being conducted?
This trial has 20 study locations across California, District of Columbia, New York, Pennsylvania, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
RECRUITING · Phase 3
-
Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention
RECRUITING · Phase 3
-
SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder
RECRUITING · Phase 3
-
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
ACTIVE NOT RECRUITING · Phase 3
-
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.